Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 20/20 | 1.00 |
| ▸ | FLT4 | P35916 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Narmafotinib SCHEMBL12479576 | 1.00 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL14635846 | 0.94 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL14635961 | 0.93 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL12479598 | 0.93 | PTK2 (0.87) | PTK2FLT4 | |
| Narmafotinib SCHEMBL38664161 | 0.92 | PTK2 (0.85) | PTK2FLT4 | |
| SCHEMBL14635552 | 0.92 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL12479033 | 0.91 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL20725570 | 0.91 | PTK2 (0.87) | PTK2FLT4 | |
| SCHEMBL14635844 | 0.91 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL12478568 | 0.91 | PTK2 (1.00) | PTK2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4595963-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE FOR INDUCING IMMUNOGENIC CELL DEATH AND USE | Inxmed (Nanjing) Co., Ltd. (CN) | 2025-08-06 | — | — | EP | claimed |
| EP-4588485-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND TOPOISOMERASE INHIBITOR AND USE THEREOF | Inxmed (Nanjing) Co., Ltd. (CN) | 2025-07-23 | — | — | EP | claimed |
| EP-4585227-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND EGFR-TKI, AND USE | Inxmed (Nanjing) Co., Ltd. (CN) | 2025-07-16 | — | — | EP | claimed |
| EP-4578449-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND MICROTUBULE INHIBITOR AND USE THEREOF | Inxmed (Nanjing) Co., Ltd. (CN) | 2025-07-02 | — | — | EP | claimed |
| CN-119947725-A | Pharmaceutical combination of FAK inhibitor and substance inducing immunogenic cell death and use thereof | 应世生物科技(南京)有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119855608-A | Pharmaceutical combination of FAK inhibitor and topoisomerase inhibitor and application thereof | 应世生物科技(南京)有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119816326-A | Pharmaceutical composition of FAK inhibitor and EGFR-TKI and application | 应世生物科技(南京)有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-20250099450-A1 | PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND USE THEREOF | INXMED (NANJING) CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| CN-119451679-A | Pharmaceutical combination of FAK inhibitor and microtubule inhibitor and application | 应世生物科技(南京)有限公司 | 2025-02-14 | — | — | CN | claimed |
| US-20250049828-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING TUMORS AND USE | INXMED (NANJING) CO., LTD. (CN) | 2025-02-13 | — | — | US | claimed |
| CN-118555961-A | Pharmaceutical composition for treating tumor and application thereof | 应世生物科技(南京)有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-118369120-A | Pharmaceutical composition for treating tumor and application thereof | 应世生物科技(南京)有限公司 | 2024-07-19 | — | — | CN | claimed |
| CN-117820298-A | Preparation method of selective oral plaque kinase inhibitor AMP-945 | 烟台皓元生物医药科技有限公司 | 2024-04-05 | — | — | CN | claimed |
| WO-2024067631-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE FOR INDUCING IMMUNOGENIC CELL DEATH AND USE | 应世生物科技(南京)有限公司 | 2024-04-04 | — | — | WO | claimed |
| WO-2024056074-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND TOPOISOMERASE INHIBITOR AND USE THEREOF | 应世生物科技(南京)有限公司 | 2024-03-21 | — | — | WO | claimed |
| WO-2024051679-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND EGFR-TKI, AND USE | 应世生物科技(南京)有限公司 | 2024-03-14 | — | — | WO | claimed |
| WO-2024041527-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND MICROTUBULE INHIBITOR AND USE THEREOF | 应世生物科技(南京)有限公司 | 2024-02-29 | — | — | WO | claimed |
| WO-2023138630-A1 | PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND USE THEREOF | 应世生物科技(南京)有限公司 | 2023-07-27 | — | — | WO | claimed |
| WO-2023104151-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING TUMORS AND USE | 应世生物科技(南京)有限公司 | 2023-06-15 | — | — | WO | claimed |
| CN-115845065-A | Use of FN/FAK pathway inhibitor in preparation of medicine for improving thyroid cancer radioiodine treatment sensitivity | 江苏省原子医学研究所 | 2023-03-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099450-A1 | PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND USE THEREOF | PTK2, BRAF, LCK | PTK2 1/4885FLT4 1076/4885 |
| US-20250049828-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING TUMORS AND USE | PTK2, SRC, CD47 | PTK2 1/4885FLT4 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.